

Press release October 20, 2022, 13.30 CET.

Sedana Medical presents at ESICM

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company will hold a scientific symposium during ESICM Lives 2022, the annual congress of the European Society of Intensive Care Medicine. Additional data on inhaled sedation will also be presented at the congress.

ESICM Lives this year will be held October 22-26 in Paris and Sedana Medical will arrange a scientific symposium on sedation in the ICU "When and for whom does sedation matter?".

"Our presence at ESICM and our scientific symposium are further important steps on our journey to establish inhaled sedation as a new standard of care in intensive care," said Johannes Doll, CEO of Sedana Medical. "We are looking forward to convening customers and opinion leaders to discuss the growing evidence base for inhaled sedation and the benefits it brings to intensive care patients."

The growing interest in inhaled sedation is also reflected in the scientific program for the congress. Among other things, two posters that build on the existing body of evidence on inhaled sedation will be presented.

German intensive care physicians present the poster "Isoflurane sedation delivered via a device with reduced dead space in intensive care patients: a prospective substudy of a randomized trial". The results show that the smaller Sedaconda ACD-S enabled isoflurane administration with lower minute ventilation without affecting ventilatory measures, compared to intravenous propofol sedation. These findings reaffirm the suitability of Sedaconda ACD-S for inhaled sedation for patients with low tidal volumes, such as those suffering from acute respiratory distress syndrome (ARDS).

From the same research group, the poster "Increased respiratory drive after prolonged isoflurane use in spontaneously breathing intensive care patients: a retrospective cohort study" will be presented. Despite a limited patient population, the results indicate that prolonged isoflurane sedation was associated with increased respiratory drive in contrast to propofol sedation. The results show that the effects of isoflurane on respiratory drive extend beyond the actual period of sedation.

Abstracts are available at [ESICM Lives website](#).

For additional information, please contact:

Johannes Doll, CEO, +46 (0)76 303 66 66

Johan Spetz, CFO, +46 (0)730 36 37 89

ir@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.

The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.



Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.